{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"22.9","value":"13.9"},{"comment":"The 95% confidence interval upper limit was not reached (i.e. insufficient number of events).","groupId":"OG001","lowerLimit":"9.5","upperLimit":"NA","value":"18.1"},{"groupId":"OG002","lowerLimit":"9.0","upperLimit":"16.3","value":"10.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"41"}],"units":"Participants"}],"description":"The progression-free survival (PFS) time is defined as the time from registration to progression or death due to any cause. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. PD: Increase of \\> 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be \\> 0.5 g/dL), Urine M-component and/or (the absolute increase must be \\> 200 mg/24 h)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. 1.0 mg/m2 Bortezomib, 4 mg Pomalidomide, 40 mg Dexamethasone","id":"OG000","title":"Phase I - Dose Level 1"},{"description":"Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. 1.3 mg/m2 Bortezomib, 4 mg Pomalidomide, 40 mg Dexamethasone","id":"OG001","title":"Phase I - Dose Level 2"},{"description":"Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. 1.3 mg/m2 Bortezomib, 4 mg Pomalidomide, 40 mg Dexamethasone","id":"OG002","title":"Phase II"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"2.5 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}